Velphoro and Heart attack - a phase IV clinical study of FDA data

Summary:

Heart attack is reported as a side effect among people who take Velphoro (sucroferric oxyhydroxide), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Veltassa, and have Hyperkalemia.

The phase IV clinical study analyzes which people have Heart attack when taking Velphoro. It is created by eHealthMe based on reports of 2,748 people who have side effects when taking Velphoro from the FDA, and is updated regularly.

What is Velphoro?

Velphoro has active ingredients of sucroferric oxyhydroxide. eHealthMe is studying from 2,749 Velphoro users. Check the latest studies of Velphoro.

What is Heart attack?

Heart attack is found to be associated with 2,482 drugs and 3,296 conditions by eHealthMe. Check the latest studies of Heart attack.

On Jul, 18, 2026

2,748 people reported to have side effects when taking Velphoro.
Among them, 14 people (0.51%) have Heart attack.

Among these 14 people:

How long have people been on Velphoro when they have Heart attack? *

What is the gender of people who have Heart attack when taking Velphoro? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Heart attack when taking Velphoro? *

What are other drugs people take besides Velphoro? *

What are other side effects people have besides Heart attack? *

Diarrhea: 3 people, 21.43%
Urinary Tract Infection: 1 person, 7.14%
Postoperative Wound Infection: 1 person, 7.14%
Nausea And Vomiting: 1 person, 7.14%
Malaise (a feeling of general discomfort or uneasiness): 1 person, 7.14%
Enteritis Infectious (infection with feline parvovirus (fpv), also known as feline panleucopenia virus): 1 person, 7.14%
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble): 1 person, 7.14%
Device Occlusion: 1 person, 7.14%
Death: 1 person, 7.14%
Cough: 1 person, 7.14%

What are the existing conditions these people have? *

Hyperkalemia (damage to or disease of the kidney): 3 people, 21.43%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 2 people, 14.29%
Phosphorus Metabolism Disorder: 2 people, 14.29%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 7.14%
Back Pain: 1 person, 7.14%
Blood Phosphorus Increased: 1 person, 7.14%
Blood Pressure Abnormal: 1 person, 7.14%
Cardiac Disorder: 1 person, 7.14%
Chest Pain: 1 person, 7.14%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Velphoro and have Heart attack?

- Check whether Heart attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Velphoro:

Velphoro (2,749 reports)

Heart attack treatments and more:

Heart attack (266,145 reports)

Browse all side effects of Velphoro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heart attack:

Heart attack (2,482 drugs)

Browse all the conditions that are associated with Heart attack:

Heart attack (3,296 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sucroferric oxyhydroxide (the active ingredients of Velphoro) and Velphoro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.